


339

BIOINFORMANT

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends



1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY

TABLE OF CONTENTS

1.	REPORT OVERVIEW	24
1.1	Statement of the Report.....	25
1.2	Executive Summary	26
1.3	Introduction	27
2.	CAR-T CELL THERAPY & CAR-T TECHNOLOGIES	29
2.1	Structure of a CAR-T Cell	29
2.2	Engineering of T Cells into CAR-T Cells	31
2.3	The Five Generations of CAR-Ts	31
2.3.1	1 st Generation CAR-T	32
2.3.2	2 nd Generation CAR-T	32
2.3.3	3 rd Generation CAR-T	33
2.3.4	4 th Generation CAR-T	34
2.3.5	5 th Generation CAR-T	35
2.4	Emerging CAR-T Technologies	35
2.4.1	In Vivo CAR-T Cell Therapy.....	35
2.4.2	Off-the-Shelf (Allogeneic) CAR-T Cells.....	36
2.4.3	Armored CAR-Ts.....	37
2.4.4	Logic-Gated CAR-T Cells	38
3.	MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2026	39
3.1	Fifteen Milestones that Shaped the CAR-T Revolution.....	40
3.1.1	First CAR Prototype (1993).....	40
3.1.2	Second-Generation CAR Invention (1998)	40
3.1.3	CD19 Target Defined (2002).....	41
3.1.4	First Adult CLL Remission (2010)	41
3.1.5	Emily Whitehead Breakthrough (2012)	41
3.1.6	First FDA Breakthrough Designation (2014).....	41
3.1.7	Historical First FDA Approval (2017)	42
3.1.8	Solidifying Adult Lymphoma Market (2017)	42
3.1.9	First Mantle Cell Lymphoma Approval (2020)	42
3.1.10	Entering Multiple Myeloma (2021)	42
3.1.11	Expansion into Autoimmune Diseases (2022).....	43
3.1.12	Solid Tumor Breakthroughs (2023).....	43
3.1.13	Allogeneic "Off-the-Shelf" Validation (2024)	43
3.1.14	Point-of-Care (Hospital Bedside) Manufacturing (2025).....	43
3.1.15	In Vivo mRNA Platforms (2026).....	44
4.	SCALABLE MANUFACTURING OF CAR-T CELL THERAPIES	45
4.1	Scalability Models	45
4.1.1	Scale-Out Model (Autologous)	45
4.1.1.1	Core Mechanics of the Scale-Out Model.....	45
4.1.1.2	Centralized Scale-Out Model.....	46
4.1.1.3	Decentralized Scale-Out Model.....	46
4.1.1.4	The End-to-End Scale-Out Workflow	46
4.1.2	Scale-Up Model (Allogeneic)	47
4.1.2.1	Core Workflow of Allogeneic Scale-Up.....	47
4.2	Currently Used CAR-T Manufacturing Platforms.....	48
4.2.1	All-in-One Integrated Instruments	48
4.2.2	The Market Leader in All-in-One Integrated Platforms	48
4.2.2.1	CliniMACS' Closest Competitor.....	49
4.2.3	Modular & Specialized Expansion Bioreactors	49
4.2.3.1	Largest-Selling Modular & Specialized Expansion Bioreactors.....	50
4.2.3.1.1	The Static Leader: Wilson Wolf G-Rex Platform	50
4.2.3.1.2	The Dynamic Leader: Cytiva Xuri W25 Cell Expansion System	50
4.3	Cost of Manufacturing Autologous CAR-T Cell Therapies	51

4.3.1	Emerging Models Altering the Cost Landscape	51
4.4	Cost of Manufacturing Allogeneic CAR-T Cell Therapies	52
5.	CAR-T PATENT LANDSCAPE	53
5.1	Cost of Filing and Securing a CAR-T Therapy Patent.....	54
5.1.1	Licensing Cost of CAR-T Cell Therapy Patents.....	54
5.1.1.1	Top 10 CAR-T Cell Therapy Licensing Deals.....	55
5.2	Number of CAR-T Cell Therapy Patent Filings, 2000 to 2026	57
5.2.1	Patent Filings for Autologous & Allogeneic CAR-T Therapies Compared	58
5.2.2	Patent Filings by CAR-T Generation Type	59
5.2.3	Patent Filings for Blood Cancers & Solid Tumors Compared, 2015-2025	60
5.2.4	CAR-T Patent Filings for Autoimmune Diseases	61
5.2.5	Patent Filings for In Vivo CAR-T Cell Therapies.....	62
5.3	Distribution of Filed CAR-T Patents by Jurisdiction.....	62
5.3.1	Top 20 CAR-T Cell Therapy Jurisdictions.....	63
5.4	Top 20 CAR-T Cell Therapy Patent Applicants	65
5.5	Top 20 CAR-T Cell Therapy Patent Inventors	66
5.6	Top 20 CAR-T Cell Therapy Patent Owners	67
5.7	Legal Status of CAR-T Cell Therapy Filed Patents	68
5.7.1	Macro Global Patent Portfolio Distribution	68
5.8	Top 20 Granted CAR-T Cell Therapy Patents.....	69
6.	EVOLVING LANDSCAPES IN CAR-T RESEARCH	72
6.1	The Bedrock Ascent of CAR-T Research Publications	72
6.2	The Allogeneic Ascent over Autologous CAR-T PubMed.gov Publications	73
6.3	The Solid Tumor Breakthrough in CAR-T Research Publications.....	74
6.4	PubMed Papers on CAR-T In Situ Revolution.....	75
6.5	CAR-T's Next Frontier in Refractory Autoimmune Remission.....	76
6.5.1	Mechanism of Action & Immune Reset	76
6.5.2	Top Clinical Indications & Successes	77
7.	THE EXPANDING MAP OF CAR-T CLINICAL TRIALS	78
7.1	Recent Trends in CAR-T Cell Therapy Clinical Trials	78
7.2	Clinical Trial Cost to Advance a Single CAR-T Cell Therapy Candidate	79
7.3	Percent Share of CAR-T Clinical Trials by CAR Generation Type.....	80
7.4	Percent Share of CAR-T Clinical Trials by Co-stimulatory Domains.....	81
7.5	Percent Share of CAR-T Clinical Trials by Target Disease.....	82
7.6	CAR-T Clinical Trials by Sponsor Type	83
7.7	Percent Share of Top 5 Hospitals & Clinical Centers in CAR-T Clinical Trials	84
7.8	Percent Share of Top 7 Companies in CAR-T Clinical Trials.....	85
7.9	Percent Share of CAR-T Clinical Trials by Top 7 Academic Institutions	86
7.10	CAR-T Clinical Trials' Study Phases	87
7.11	Funders of CAR-T Clinical Trials	88
8.	CAR-T FUNDING LANDSCAPE	89
8.1	Venture Capital Funding in CAR-T Sector, 2024-2026	89
8.1.1	Legend Biotech	90
8.1.2	Waypoint Bio	90
8.1.3	CREATE Medicines, Inc.	90
8.1.4	Orca Bio	91
8.1.5	Orum Therapeutics	91
8.1.6	Syneron Bio.....	91
8.1.7	Link Cell Therapies	92
8.1.8	MagicRNA Biotech.....	92
8.1.9	Wugen	92
8.1.10	Innovacell	93
8.1.11	Anocca	93
8.1.12	Strand Therapeutics.....	93
8.1.13	ArsenalBio.....	94
8.1.14	Capstan Therapeutics	94

8.1.15	YolTech Therapeutics	94
8.2	CAR-T Collaboration Deals, 2023- July, 2026.....	95
8.2.1	Johnson & Johnson/Sail Biomedicines	96
8.2.2	Circio Holding ASA & Tcelltech GmbH	96
8.2.3	Helix Cell Therapeutics & Biocell Innovations	96
8.2.4	Applied Cells, Inc. & Immuneel Therapeutics	96
8.2.5	Dispatch Bio & CARsgen Therapeutics	97
8.2.6	Cellares & University of Wisconsin School of Medicine.....	97
8.2.7	A-SEEDS, Co., Ltd. & Cell Therapies Pty Ltd.....	97
8.2.8	Kytopen Corporation & Excellos, Inc.	98
8.2.9	Kelonia Therapeutics & Janssen Biotech, Inc.	98
8.2.10	Gilead's Kite Pharma & Pregene Biopharma.....	98
8.2.11	Gilead's Kite Pharma & Interius BioTherapeutics	99
8.2.12	Proton Advanced Solutions & EVA Pharma	99
8.2.13	Vector BioMed & Muni Seva Ashram.....	99
8.2.14	Gilead's Kite Pharma & Arcellx	100
8.2.15	Caring Cross & ImmunoACT	100
8.2.16	Bristol Myers Squibb & Cellares	100
8.2.17	Gilead Sciences (Kite) & Arcellx	101
8.2.18	ImmunoACT, IIT Bombay, & Tata Memorial Centre	101
8.2.19	Janssen Biotech & Cellular Biomedicine Group	101
8.2.20	Johnson & Johnson and Novartis	101
8.3	Merger & Acquisition Deals in CAR-T Therapy Sector.....	102
8.3.1	Merger & Acquisition in 2026	102
8.3.1.1	Johnson & Johnson Acquires Sail Biomedicines	103
8.3.1.2	Liminatus Pharma Acquires InnocsAI LLC	103
8.3.1.3	Gilead Sciences, Inc. Acquires Arcellx, Inc.	103
8.3.1.4	Eli Lilly Acquires Kelonia Therapeutics.....	104
8.3.1.5	Eli Lilly Acquires Orna Therapeutics.....	104
8.3.1.6	Bristol Myers Squibb Acquires Orbital Therapeutics	104
8.3.1.7	AbbVie Acquires Capstan Therapeutics.....	105
8.3.1.8	AstraZeneca Acquires Esco Biotec	105
8.3.1.9	Roche Acquires Poseida Therapeutics	105
8.3.1.10	AstraZeneca Acquires Gracell Biotechnologies	106
8.4	IPO Funding Raised by CAR-T Companies in Recent Years	107
8.4.1	Legend Biotech	107
8.4.2	Caballetta Bio.....	108
8.4.3	Editas Medicine	108
8.4.4	Allogene Therapeutics	108
8.4.5	Artiva Biotherapeutics	109
8.4.6	Autolus Therapeutics	109
8.4.7	Kyverna Therapeutics	109
9.	GLOBALLY APPROVED CAR-T CELL THERAPIES	110
9.1	Kymriah (tisagenlecleucel).....	111
9.1.1	Product Description	111
9.1.2	Foundational Technology.....	111
9.1.2.1	Patent Protection	112
9.1.3	Indications Approved for Kymriah	112
9.1.3.1	Dates of Approvals for Different Indications	112
9.1.4	Marketing Status	113
9.1.5	Development Timeline for Kymriah.....	113
9.1.6	Manufacturing of Kymriah	114
9.1.6.1	Manufacturing Locations.....	114
9.1.7	Certified Kymriah Treatment Centers	114
9.1.8	Cost of Treatment	115
9.1.8.1	Estimated Out-of-Pocket Costs & Regional Variations	115

9.1.9	Competing Therapies with Kymriah	115
9.1.10	Revenue Generation by Kymriah	116
9.2	Yescarta (axicabtagene ciloleucel)	116
9.2.1	Product Description	117
9.2.2	Foundational Technology	117
9.2.2.1	Patent Protection	117
9.2.3	Indications Approved for Yescarta	118
9.2.4	Approval of Yescarta in Different Countries	118
9.2.5	Development Timeline of Yescarta	119
9.2.6	Manufacturing Process	120
9.2.6.1	Manufacturing Locations	120
9.2.7	Treatment Centers	121
9.2.8	Treatment Cost	121
9.2.9	Competing Therapies	121
9.2.10	Revenue Generation	122
9.3	Tecartus (brexucabtagene autoleucel)	122
9.3.1	Product Description	122
9.3.2	Foundational Technology & Patent Protection	123
9.3.3	Indications Approved for Tecartus	123
9.3.4	Dates of Approvals	123
9.3.5	Development Timeline	124
9.3.6	Manufacturing Process	124
9.3.6.1	Manufacturing Location	125
9.3.7	Cost of Treatment	125
9.3.8	Competing Therapies	125
9.3.9	Revenue Generation	126
9.4	Breyanzi (lisocabtagene maraleucel)	126
9.4.1	Product Description	126
9.4.2	Foundational Technology	127
9.4.2.1	Patent Protection	127
9.4.3	Approved Indications for Breyanzi	127
9.4.4	Dates of Approval by Country/Region	128
9.4.5	Development Timeline	128
9.4.6	Manufacturing Process	129
9.4.6.1	Manufacturing Locations	129
9.4.7	Authorized Treatment Centers	130
9.4.7.1	Cost of Treatment	130
9.4.8	Competing Therapies	130
9.4.9	Revenue Generation	131
9.5	Abecma (idecabtagene vicleucel)	131
9.5.1	Product Description	132
9.5.2	Foundational Technology	132
9.5.3	Patent Protection	133
9.5.4	Approved Indications	133
9.5.5	Dates of Approval	133
9.5.6	Development Timeline	134
9.5.7	Manufacturing Process	134
9.5.7.1	Manufacturing Location	135
9.5.8	Certified Treatment Centers	135
9.5.9	Treatment Cost	135
9.5.10	Competing Therapies	135
9.5.11	Revenue Generation	136
9.6	Carvykti (ciltacabtagene autoleucel)	136
9.6.1	Product Description	136
9.6.2	Foundational Technology	137
9.6.2.1	Patent Protection	137

9.6.3	Approved Indications.....	137
9.6.4	Dates of Approval.....	138
9.6.5	Development Timeline of Carvykti	138
9.6.6.1	Manufacturing Locations.....	139
9.6.7	Certified Treatment Centers.....	139
9.6.8	Cost of Treatment	140
9.6.9	Competing Therapies.....	140
9.6.10	Revenue Generation	140
9.7	Aucatzyl (obecabtagene autoleucel)	141
9.7.1	Product Description.....	141
9.7.2	Foundational Technology.....	141
9.7.2.1	Patent Protection	141
9.7.3	Approved Indications.....	142
9.7.3	Dates of Approval.....	142
9.7.4	Marketing Status	142
9.7.5	Development Timeline	142
9.7.6	Manufacturing	143
9.7.7	Manufacturing Location.....	143
9.7.8	Cost of Treatment	143
9.7.9	Other Competing Therapies.....	144
9.7.10	Revenue Generation	144
9.8	Carteyva (relmacabtagene autoleucel).....	144
9.8.1	Product Description.....	144
9.8.2	Foundational Technology.....	145
9.8.3	Approved Indications.....	145
9.8.4	Dates of Approval.....	146
9.8.5	Marketing Status	146
9.8.6	Development Timeline	146
9.8.7	Manufacture	147
9.8.8	Manufacturing Location.....	147
9.8.9	Cost of Treatment	147
9.8.10	Competing Therapies.....	147
9.8.11	Revenue Generation	148
9.9	Yikaida (axicabtagene ciloleucel)	148
9.9.1	Product Description.....	148
9.9.2	Foundational Technology.....	149
9.9.2.1	Patent Protection	149
9.9.3	Approved Indications.....	150
9.9.4	Dates of Approval.....	150
9.9.5	Marketing Status	150
9.9.6	Development Timeline	151
9.9.7	Manufacturing Process	151
9.9.7.1	Manufacturing Location	152
9.9.8	Certified Treatment Centers.....	152
9.9.9	Cost of Treatment	152
9.9.10	Approved Competing Therapies	152
9.9.11	Revenue Generation	153
9.10	Zevor-cel (Zevorcabtagene Autoleucel)	153
9.10.1	Product Description.....	153
9.10.2	Foundational Technology.....	154
9.10.3	Approved Indications.....	154
9.10.4	Approval Date	154
9.10.5	Development Timeline	154
9.10.6	Manufacturing	155
9.10.6.1	Manufacturing Locations	155
9.10.7	Certified Treatment Centers.....	156

9.10.8	Cost of Treatment	156
9.10.9	Approved Competing Therapies	156
9.10.10	Revenue Generation.....	157
9.11	Yorwida (inaticabtagene autoleucel)	157
9.11.1	Product Description.....	157
9.11.2	Foundational Technology.....	158
9.11.3	Approved Indications.....	158
9.11.4	Dates of Approval.....	158
9.11.5	Marketing Status	158
9.11.6	Development Timeline	158
9.11.7	Manufacturing	159
9.11.7.1	Manufacturing Location	160
9.11.8	Authorized Treatment Centers.....	160
9.11.9	Cost of Treatment	160
9.11.10	Approved Competing Therapies.....	160
9.12	Fucaso (equecabtagene autoleucel)	161
9.12.1	Product Description.....	161
9.12.2	Foundational Technology.....	161
9.12.2.1	Patent Protection.....	162
9.12.3	Approved Indications.....	162
9.12.4	Dates of Approval.....	162
9.12.5	Marketing Status	163
9.12.6	Development Timeline	163
9.12.7	Manufacturing	163
9.12.7.1	Manufacturing Locations	164
9.12.8	Cost of Treatment	164
9.12.9	Competing Approved Therapies	165
9.13	Satri-cel (Satricabtagene Autoleucel)	165
9.13.1	Product Description.....	165
9.13.2	Approved Indications.....	166
9.13.3	Date of Approval	167
9.13.4	Marketing Status	167
9.13.5	Development Timeline	167
9.13.6	Manufacturing Process	168
9.13.6.1	Manufacturing Location	168
9.13.7	Certified Treatment Centers.....	168
9.13.8	Cost of Treatment	169
9.13.9	Approved Competing Therapies	169
9.14	Qartemi (varnimcabtagene autoleucel)	169
9.14.1	Product Description.....	169
9.14.2	Foundational Technology.....	170
9.14.3	Approved Indications.....	170
9.14.4	Dates of Approval.....	170
9.14.5	Marketing Status	170
9.14.6	Development Timeline	170
9.14.7	Manufacturing	171
9.14.7.1	Manufacturing Location	171
9.14.8	Certified Treatment Centers.....	171
9.14.9	Cost of Treatment	172
9.14.10	Approved CAR-T & Non-CAR-T Competing Therapies	172
9.14.11	Revenue Generation.....	172
9.15	NexCAR19 (talicabtagene autoleucel)	173
9.15.1	Product Description.....	173
9.15.2	Foundational Technology.....	173
9.15.3	Approved Indications.....	173
9.15.4	Date of Approval	174

9.15.5	Marketing Status	174
9.15.6	Development Timeline	174
9.15.7	Manufacturing	175
9.15.7.1	Manufacturing Location	175
9.15.9	Certified Treatment Centers.....	175
9.16	RIMQARTO® (anbalcabtagene autoleucl)	175
9.16.1	Product Description.....	176
9.16.2	Foundational Technology.....	176
9.16.3	Approved Indications.....	176
9.16.4	Date of Approval	176
9.16.5	Marketing Status	177
9.16.6	Development Timeline	177
9.16.7	Manufacturing	178
9.16.7.1	Manufacturing Location	178
10.	MOST ANTICIPATED CAR-T APPROVALS BETWEEN 2026 AND 2036	179
10.1	Yescarta as Frontline CAR-T Cell Therapy	179
10.2	Breyanzi as Frontline CAR-T Cell Therapy	179
10.3	KYV-101 for Autoimmune Diseases	179
10.4	Dual-Targeting Standard (CD19/CD20 CAR-Ts).....	180
10.4.1	Dual-Targeting JNJ-4496	180
10.4.2	Dual-Targeting KITE-363	180
10.5	ALLO-501A/Cema-cel (Allogeneic "Off-the-Shelf")	180
10.6	CTX112 Next-Gen CRISPR-Edited CAR-T	181
10.7	JV-394 CAR-T Targeting CD7/CD5/CD94	181
10.8	KIR-CAR-T Cell Therapies for Solid Tumors.....	181
10.9	FT819 iPSC-Derived Cellular Therapy	182
10.9.1	Key Engineering Modifications in FT819	182
10.9.2	Clinical Milestones & Trial Updates for FT819.....	182
10.10	In Vivo CAR-T Therapeutics (The "No-Lab" Alternative)	183
10.10.1	Cutting-Edge In Vivo CAR-T Candidates in Clinical Trials	183
10.10.1.1	KLN-1010 (inMMycAR Trial).....	184
10.10.1.2	INT2104.....	184
10.10.1.3	ORN-252/Orna Therapeutics	184
10.11	CAR-Ts targeting Fibrosis and Senescence	184
10.12	UCARTFAP	184
10.13	FAP-Targeted In Vivo mRNA-LNP	185
11.	CAR-T UTILIZATION, COST OF DEVELOPMENT AND TREATMENT	186
11.1	Utilization in the U.S.	186
11.2	Utilization in Europe	186
11.3	Utilization in Asia/Pacific.....	187
11.4	Medical Tourism in the Context of CAR-T Treatment	188
11.4.1	Top Global Hubs for CAR-T Medical Tourism	188
11.4.1.1	Value of CAR-T Treatment through Medical Tourism	189
11.4.1.2	Hidden Costs and "Total Budget" Math for Travelers	189
11.4.2	Two Prominent Destinations for International Patients.....	190
11.4.2.1	Turkey.....	190
11.4.2.1.1	Top Hospitals & Accreditations in Turkey	190
11.4.2.2	India.....	191
11.4.2.2.1	Patient Demographics by Region	191
11.4.2.2.2	Key Indian Centers Accommodating Foreign Patients	191
11.5	Manufacturing Cost of CAR-T Cell Therapy	192
11.5.1	Cost of Developing CAR-T Therapy from Discovery to Marketing Approval	192
11.5.2	Cost of Developing CAR-T Therapy from Academics to Spinouts	193
11.6	Cost of CAR-T Treatments across Geographies.....	193
11.6.1	Total Treatment Cost for CAR-T Cell Therapies in the United States	194
11.6.2	Total CAR-T Treatment Cost in Europe.....	195

11.6.3	Total CAR-T Treatment Cost in Japan.....	195
11.6.4	Total CAR-T Treatment Cost in South Korea	196
11.6.5	Total CAR-T Treatment Cost in Australia	196
11.6.6	Total CAR-T Treatment Cost in China	197
11.6.7	Total CAR-T Treatment Cost in India.....	197
12.	DISEASES TREATED WITH CAR-T CELL THERAPIES	198
12.1	Blood Cancers	198
12.1.1	Acute Lymphoblastic Leukemia (ALL)	199
12.1.2	B-Cell Lymphomas.....	199
12.1.3	Multiple Myeloma	200
12.2	Autoimmune diseases	201
12.2.1	Systemic Lupus Erythematosus (SLE)	201
12.2.1.1	CAR-T Development for SLE	201
12.2.2	Multiple Sclerosis (MS)	202
12.2.3	Pemphigus Vulgaris (PV)	203
12.2.3.1	Development of CAR-T for PV	203
12.2.4	Systemic Sclerosis (SSc).....	203
12.2.4.1	CAR-T Development for SSc	204
12.2.4.1.1	Prominent CAR-T Clinical Trial Candidates for SSc.....	204
12.3	Solid Tumors.....	204
12.3.1	Gastrointestinal & Abdominal Cancers	204
12.3.2	Brain & Central Nervous System (CNS) Tumors	205
12.3.3	Lung and Thoracic Cancers.....	205
12.3.4	Pediatric and Musculoskeletal Cancers	206
12.4	Infectious and Senescence-Associated Diseases.....	206
12.4.1	CAR-T Applications in Infectious Diseases	206
12.4.2	CAR-T Applications in Senescence-Associated Diseases	207
12.5	The Clinical Superiority of CAR-T Cell Therapy over Non-CAR-T Therapies	207
12.5.1	"Living Drug" Dynamics (Long-Term Vigilance).....	207
12.5.2	MHC-Independent Target Recognition	208
12.5.3	Laser-Focused Specificity.....	208
12.5.4	Single Infusion vs. Continuous Treatment Cycles	208
13.	MARKET ANALYSIS.....	209
13.1	Global Market for CAR-T Cell Therapy Products	211
13.1.1	Sales of FDA-Approved CAR-T Cell Therapy Products between 2017 and 2025	212
13.1.2	Sales History of CAR-T Cell Therapies Approved in China.....	214
13.1.3	Sales History of Approved CAR-T Cell Therapies in India	217
13.1.4	RIMQARTO: The South Korean Approved CAR-T	218
13.1.4.1	The Reimbursement Gateway (The Ultimate Sales Driver)	218
13.1.4.2	Pricing and Cost Competitiveness	219
13.1.4.3	Clinical Edge Driving Market Capture	219
13.2	Estimated Global Market for CAR-T Cell Therapies, 2025-2035	220
13.2.1	Global CAR-T Cell Therapy Market by Targeted Antigens, 2017-2025	222
13.2.2	Estimated Global Market for CAR-T Therapies by Target Antigen, 2025-2035	223
13.3	Global CAR-T Market by Indication	224
13.3.1	The Percent Share of CAR-T Market by Approved Indications	225
13.3.1.1	Global CAR-T Market by Lymphoma Sub-Type.....	227
13.3.1.2	CAR-T Market for Multiple Myeloma by Sub-Type.....	228
13.3.2	CAR-T Market for Leukemia Indications	229
13.3.3	CAR-T for Solid Tumor Indications	229
14.	CATEGORIES OF CAR-T COMPANIES.....	231
14.1	Key CAR-T Companies by Generation and Signaling.....	231
14.2	Next-Generation CAR-Ts.....	232
14.2.1	Comparison of Second Generation & Next-Generation CAR-Ts.....	232
14.3	CAR-T Companies by Cellular Source (Autologous vs. Allogeneic)	233
14.4	CAR-T Companies by Gene Editing/Modification Technology	233

14.5	CAR-T Companies by Targeting and Logic Gate Technology	234
14.6	CAR-T Companies by Indication Specialization	235
14.7	CAR-T Companies by Production model.....	236
14.8	Percent Shares of Autologous & Allogeneic CAR-T Companies	237
14.9	Percent Share of CAR-T Companies by Generation Types	237
15.	COMPANY PROFILES	239
15.1	4immune Therapeutics	239
15.1.1	CAL/CAR-T Cell Therapy Platform	239
15.2	A2 Biotherapeutics, Inc.	240
15.2.1	Tmod™	240
15.2.2	A2 Biotherapeutics' RD Pipeline	241
15.3	AAX Biotech AB	241
15.3.1	Seqitope®	242
15.3.2	Opti-mAb®	242
15.4	AbbVie	242
15.4.1	Key CAR-T Programs & Partnerships.....	243
15.5	AbClon	243
15.5.1	NEST Platform	243
15.5.2	zCAR-T Platform	244
15.5.3	AbClon's CAR-T Product Candidates	244
15.6	AbelZeta Pharma	245
15.6.1	RMAT designation for C-CAR168.....	245
15.6.2	Armored CAR-T Technology.....	245
15.6.3	GPC3-Targeting CAR-T (C-CAR031).....	245
15.7	Adicet Bio.....	246
15.7.1	Leading Clinical Candidates	247
15.8	Alaya.bio	247
15.8.1	Core Technology.....	247
15.8.2	Partnerships & Milestones	248
15.9	Aleta Biotherapeutics	248
15.9.1	CAR-T Engagers (CTEs)	248
15.10	Allogene Therapeutics.....	249
15.10.1	AlloCAR T™ Platform	249
15.10.2	Dagger™ Technology.....	250
15.10.3	TurboCAR™ technology.....	250
15.10.4	ALLO-647 (Lymphodepletion)	250
15.10.5	Cloak™ Technology	250
15.11	Allogenica	251
15.11.1	Pre-T Cell Technology	251
15.11.2	AlloCAR T™	252
15.12	AlloTera Therapeutics	252
15.12.1	Core Technology & Pipeline	252
15.13	Alpha Biopharma.....	253
15.13.1	CAR-T Cell Therapy Context & Pipeline.....	253
15.14	Angeles Therapeutics.....	254
15.14.1	Synthetic Immune Receptor-T (SIR-T™) platform	254
15.15	Anixa Biosciences	254
15.15.1	CAR-T Program	255
15.16	Antion Biosciences SA	255
15.16.1	Core CAR-T Technologies.....	255
15.16.2	Key CAR-T Pipeline Programs	256
15.16.3	Strategic Partnerships	256
15.17	Arbele Limited.....	256
15.17.1	Arbele's CAR-T and Immuno-Oncology Approach.....	257
15.18	Arcellx, Inc.	257
15.18.1	Lead Therapy (Anito-cel)	257

15.18.2	ARC-SparX platform	258
15.18.3	Acquisition by Gilead Sciences	258
15.19	ArsenalBio	259
15.19.1	CITE Platform	259
15.19.2	Key Pipeline Programs	259
15.20	A-SEEDS Co., Ltd.	260
15.20.1	Core Focus & Business Operations	260
15.21	AstraZeneca	261
15.21.1	Key CAR-T Assets & Strategy	261
15.21.2	Disruptive "In Vivo" Technology	261
15.21.3	Expansion beyond Oncology	262
15.22	Atara Biotherapeutics	262
15.22.1	Allogeneic EBV T-Cell Platform	262
15.23	Autolus Therapeutics	263
15.23.1	Modular CAR T-Cell Engineering	263
15.23.2	Fast Off-Rate Binding CARs	264
15.23.3	R&D Pipeline	264
15.24	AvenCell Therapeutics, Inc.	265
15.24.1	Universal Switchable CAR Platform (UniCAR/RevCAR)	265
15.24.2	UniCAR	265
15.24.3	RevCAR	265
15.24.4	R&D Pipeline	266
15.25	Beam Therapeutics	266
15.25.1	Multiplex Base Editing	266
15.25.2	BEAM-201	267
15.26	BeiCell Therapeutics	267
15.26.1	Technology: The CiPSC Platform	267
15.26.2	Approaches to CAR-T Cell Therapy	268
15.27	Bio4t2	268
15.27.1	PrismCore™	269
15.27.2	Bio-Strike™	269
15.28	BioNTech SE	269
15.28.1	CARVac	269
15.28.2	Product Candidates	269
15.28.2.1	BNT211 (CLDN6 CAR-T + CARVac)	270
15.28.2.2	BNT314/GEN1059	270
15.29	BrainChild Bio	271
15.29.1	Multiplex Targeting	271
15.29.2	BCB-276: The Lead Candidate	271
15.30	Bristol Myers Squibb	272
15.30.1	Approved CAR-T Products	272
15.30.1.1	Breyanzi (lisocabtagene maraleucel)	272
15.30.1.2	Abecma (idecabtagene vicleucel)	273
15.30.2	Product Candidates in ongoing Clinical Trials	273
15.31	BioAgilytix	274
15.31.1	Key Services for CAR-T Development	274
15.32	BioOra	275
15.32.1	Atla-cel (WZTL-002)	275
15.33	Biosceptre International Limited	276
15.33.1	BRIDGE CAR™	276
15.33.2	R&D Pipeline	276
15.34	Cabaletta Bio	277
15.34.1	CARTA (Chimeric Antigen Receptor T cells for Autoimmunity)	277
15.34.2	CAAR T (Chimeric Autoantibody Receptor T cells)	277
15.34.3	R&D Programs	277
15.35	Capstan Therapeutics	278

15.35.1	Core Technology	278
15.35.2	Pipeline & Focus Areas	279
15.36	Caravan Biologix	279
15.36.1	Mini-CAR™ Technology	280
15.36.2	Mini-VAN™ Technology	280
15.37	CARBio Therapeutics	280
15.37.1	Core Focus & Pipeline	280
15.38	Caribou Biosciences	281
15.38.1	chRDNA (CRISPR hybrid RNA-DNA)	281
15.38.2	Caribou's Clinical Programs	281
15.39	Carina Biotech	282
15.40	Caring Cross	283
15.40.1	Core Mission & Approach	283
15.40.2	Key Therapeutic Pipelines	283
15.40.3	Global Collaborations	284
15.41	Caris Life Sciences	284
15.41.1	ADAPT™ Platform	284
15.41.2	CODEai™ Data Platform	285
15.42	CARsgen Therapeutics	285
15.42.1	THANK-uCAR®	285
15.42.2	CycloCAR®	286
15.42.3	LADAR®	286
15.42.4	CARvivo™	286
15.42.5	CARsgen's R&D Pipeline	286
15.43	CARTemis Therapeutics GmbH	287
15.43.1	Core Focus & Partnerships	287
15.43.2	TQ's CELLfinity Platform	287
15.44	Cartesian Therapeutics	288
15.44.1	The RNA Armory® Platform	288
15.44.2	Cartesian's R&D Programs	288
15.45	Cell-Easy	289
15.46	Cellectis	289
15.46.1	UCART	289
15.46.2	Smart CAR-T	290
15.47	Cellepup Therapeutics	290
15.47.1	Core CAR-T Development & Technology	290
15.48	Cellergy Pharma, Inc.	291
15.48.1	IgE-Targeting CAR-T Platform Technology	291
15.49	Cellinfinity Bio	292
15.49.1	Core Technology and Innovations	292
15.49.2	Key Therapeutic Pipeline	293
15.50	Cellipont Bioservices	293
15.50.1	Core Competencies in CAR-T & Cell Therapy	293
15.50.2	Facilities & Infrastructure	294
15.50.3	Notable CAR-T Industry Partnerships	294
15.51	Cell Therapies Pty Ltd	295
15.51.1	Key CAR-T Services	295
15.52	Celluris	296
15.52.1	RefuaPepCAR (RfuCAR) Technology	296
15.53	Celularity Inc.	297
15.53.1	Placental-Derived Advantage	297
15.53.1.1	Off-the-Shelf (Allogeneic) Capabilities	297
15.53.2	Key Pipeline Assets	297
15.53.3	Proprietary Technology Platform	298
15.54	Celyad Oncology SA	298
15.54.1	shRNA-Based Allogeneic Platform	298

15.55	Century Therapeutics	299
15.55.1	Allo-Evasion Technology	299
15.55.2	R&D Focus	299
15.56	Chimera Bioengineering	300
15.56.1	Core Technology & Platforms	300
15.56.2	Focus in CAR-T Therapy	301
15.57	Chimeric Therapeutics	301
15.57.1	CHM 2101	301
15.57.2	The 3 rd Generation CAR-T	302
15.58	Circio Holding ASA	303
15.58.1	How Circio's Platform Relates to CAR-T	303
15.58.2	Strategic Partnerships & Pipeline	303
15.59	COEPTIS Therapeutics	304
15.59.1	SNAP-CAR Technology	304
15.59.2	How SNAP-CAR Works	304
15.59.2.1	Key Benefits of the Technology	305
15.59.2.2	Current Applications and Development	305
15.60	CREATE Medicines	306
15.60.1	Key CAR-T Programs	306
15.61	CrisprBits	307
15.61.1	CrisprBits in the Context of CAR-T Cell Therapies	307
15.62	CRISPR Therapeutics AG	308
15.62.1	CRISPR/cas9	308
15.62.2	Key Allogeneic CAR-T Candidates	309
15.63	Crown Bioscience	309
15.63.1	Crown Bio's CAR-T Services	309
15.64	Curocell	310
15.64.1	OVIS™ (Overcome Immune Suppression) Platform	310
15.64.2	Solid Tumor CAR-T Platform	310
15.64.3	Allogeneic (Off-the-Shelf) CAR-T Technology	311
15.64.4	R&D Programs	311
15.65	Currus Biologics Pty Ltd	312
15.66	Cyteph Pty Ltd	312
15.66.1	Core Technology: Cyt-ATTAC Platform	313
15.66.1.1	CYT-AT1	313
15.67	Cytoart, Inc.	314
15.67.1	CAR-T Related Services	314
15.68	Dispatch Bio	315
15.68.1	Core Technology: The Flare™ Platform	315
15.68.2	Clinical Pipeline & Partnerships	315
15.69	Dynamic Cell Therapies, Inc.	316
15.69.1	Core Technology: Controllable CAR-T System	316
15.69.2	Therapeutic Pipeline & Indications	316
15.70	EdiGene	317
15.70.1	Core Technology Platforms	317
15.70.2	Key Pipeline Programs	318
15.71	Editas Medicine	318
15.71.1	SLEEK Technology	318
15.71.2	Editas Medicine's CAR-Programs	319
15.72	Elicera Therapeutics AB	319
15.72.1	iTANK Technology	320
15.72.2	Key Product Pipeline Candidates	320
15.73	Eli Lilly	320
15.73.1	Strategic Acquisitions and Pipeline	321
15.73.2	The Shift to In Vivo Technologies	321
15.74	Elpis Biopharmaceuticals	321

15.74.1	Proprietary Technology Platforms	322
15.74.2	Lead CAR-T Pipeline Candidates	322
15.74.3	Key Partnerships and Clinical Trials	322
15.75	Epigenic Therapeutics	323
15.75.1	EPIREG® Platform	323
15.75.2	Epigenic Therapeutics & CAR-T Cell Therapy	324
15.75.3	Core Technology Platforms	324
15.76	EsoBiotec	325
15.76.1	The ENaBL Platform	325
15.76.2	Pipeline & Clinical Status	326
15.77	Essen BioTech	326
15.78	Eureka Therapeutics	327
15.78.1	CAR-T Product Candidate	327
15.79	EVA Pharma	327
15.79.1	Moves in CAR-T Therapy	328
15.80	EXUMA Biotech	328
15.80.1	GCAR Platform	328
15.80.2	rPOC SC Platform	329
15.80.3	CD3-Targeted LVV	329
15.80.4	Tumor Metabolism Regulated (TMR) CARs	329
15.80.5	FITNESS DRIVER	329
15.80.6	Synthetic CAR Ligands (SCL)	329
15.80.7	EXUMA Biotech's R&D Pipeline	330
15.81	FastBack Bio	330
15.81.1	M-STIM Platform	331
15.82	Fate Therapeutics	331
15.82.1	1XX CAR Technology	331
15.82.2	Sword and Shield™ Technology	332
15.82.3	Alloimmune Defense Receptor (ADR) Technology	332
15.82.4	CAR-T-Based R&D Programs	332
15.83	Fosun Pharma	333
15.83.1	Key CAR-T Milestones and Corporate Strategy	333
15.83.2	Patient Accessibility and Affordability	334
15.84	Galapagos NV	334
15.84.1	Galapago's "Pont-of-Care" CAR-T Platform	334
15.85	Gencyte Therapeutics	335
15.85.1	PMA CAR Technology	335
15.86	Genentech Inc.	336
15.86.1	Current CAR-T Collaborations and Focus	336
15.87	Gilead Sciences	337
15.87.1	Key CAR-T Marketed Therapies	337
15.87.2	Strategic Pipeline and Growth	337
15.88	Gennova Biopharmaceuticals	338
15.88.1	Gennova's Role in CAR-T Cell Therapy	338
15.88.2	Gennova's Strategic Direction	339
15.89	GlycoMantra	339
15.89.1	Context in CAR-T Cell Therapy	339
15.90	GoCART Therapeutics	340
15.90.1	Technology & Platform	340
15.91	Gracell Biotechnologies	341
15.91.1	FasTCAR	341
15.91.2	TrUCAR	341
15.91.3	SMART CART	341
15.91.4	Key Clinical Programs	342
15.92	Guangzhou Biogene Biotech Co., Ltd.	342
15.92.1	Rapid Target Screening and Validation Platform	342

15.92.2	Rapid Autologous CAR-T Manufacturing Platform	343
15.92.3	Off-the-shelf CAR-T Platform.....	343
15.92.4	In Vivo Modified CAR-T Platform.....	343
15.92.5	Guangzhou Bio-gene's R&D Pipeline.....	343
15.93	Gyala Therapeutics	344
15.93.1	Key Pillars of Gyala Therapeutics' Focus	344
15.94	IASO Biotherapeutics	345
15.94.1	Equecabtagene Autoleucel (eque-cel)	345
15.95	iCell Gene Therapeutics, LLC	346
15.95.1	Compound CARs (cCARs)	347
15.95.2	Non-Gene Editing CAR Technology	347
15.95.3	Universal CARs (Super NK-Cells)	347
15.95.4	Universal CARs (Super NK-Cells)	347
15.96	Immuneel Therapeutics.....	348
15.96.1	Qartemi (varnimcabtagene autoleucel)	348
15.97	ImmunoACT	350
15.97.1	NexCAR19 (Talicabtagene autoleucel)	350
15.98	Immunofoco.....	351
15.98.1	Peri Cruiser® Platform.....	351
15.98.2	SolidGuard	351
15.98.3	Lentiviral-based In Vivo CAR-T Platform	352
15.98.4	Immunofoco's R&D Pipeline	352
15.99	Immunopharm Technology Co., Ltd.	353
15.99.1	Core Focus & Pipeline	353
15.100	Inceptor Bio	354
15.100.1	OUTLAST Platform.....	354
15.100.2	IBT-101	354
15.101	Innovative Cellular Therapeutics	355
15.101.2	CoupledCAR® Platform Technology	355
15.101.3	INSTACAR™ Platform.....	355
15.101.4	ARMOREDCAR™ Platform.....	355
15.101.5	InvivoCAR Platform	356
15.101.6	R&D Programs.....	356
15.102	Intellia Therapeutics	357
15.102.1	Universal CAR-T	357
15.102.2	Intellia Therapeutics' CAR-T R&D Programs	358
15.103	Invectys, Inc.....	358
15.103.1	Core Technology & Pipeline	358
15.104	iO BiO Sciences	359
15.104.1	Technology Platform.....	359
15.104.2	Clinical & Therapeutic Focus	359
15.105	Janssen Pharmaceuticals	360
15.105.1	Flagship Therapy: Carvykti (Cilta-cel)	360
15.105.2	Key Partnerships and Pipeline	360
15.106	Jiangsu Pacific Meinuo Biopharmaceuticals Co., Ltd.	361
15.106.1	Key CAR-T Programs in the Pipeline	361
15.107	JW Therapeutics.....	362
15.107.1	Key Products & Pipeline	362
15.108	Kelonia Therapeutics.....	363
15.108.1	iGPS® Platform	363
15.109	Kincell Bio.....	364
15.109.1	Core Focus Areas in the CAR-T Space.....	364
15.109.2	Facilities and Infrastructure.....	365
15.110	Kiragen Bio.....	365
15.110.1	KiraLOGIC Platform.....	365
15.111	Kite Pharma.....	366

15.111.1	Yescarta® (axicabtagene ciloleucel)	366
15.111.2	Tecartus® (brexucabtagene autoleucel)	367
15.111.3	Bicistronic CAR-T Therapy	367
15.112	Kytopen Corp.....	368
15.112.1	Kytopen's Role & Technology.....	368
15.112.3	Key CAR-T Partnerships & Milestones.....	368
15.113	Kyverna Therapeutics	369
15.113.1	SmarTcell™ platform	369
15.113.2	Ingenui-T™ Manufacturing Platform.....	369
15.114	Legend Biotech Corporation.....	370
15.114.1	Core Technology Platforms	370
15.114.2.1	CARVYKT1® (ciltacabtagene autoleucel)	371
15.114.3	Pipeline Candidates	371
15.115	Leman Biotech Co., Ltd.	372
15.115.1	Clinical Breakthroughs.....	372
15.115.2	Core Technology & Partnerships.....	372
15.116	Leucid Bio	373
15.116.1	Lateral CAR-T Platform	373
15.116.2	Pipeline Lead Asset: LEU011	373
15.117	Liminatus Pharma	374
15.117.1	Core Therapeutics & Pipeline	374
15.118	Link Cell Therapies.....	375
15.118.1	Logic-Gated CAR-T	375
15.119	Luminary Therapeutics	376
15.119.1	Technology	376
15.120	Lyell Immunopharma.....	377
15.120.1	Key Reprogramming Technologies	377
15.120.2	Lyell Immunopharma's R&D Programs	377
15.121	March Biosciences, Inc.	378
15.121.1	Pipeline & Technology	378
15.122	MaxCyte, Inc.....	379
15.122.1	The EXPERT GTx® system.....	379
15.122.2	Company Focus and Core Technology	379
15.122.3	Strategic Impact of EXPERT GTx on CAR-T and Cell Therapy	380
15.122.4	Industry Adoption of EXPERT GTx	380
15.123	MedTherapy Biotech	380
15.123.1	Core Services & Platforms.....	381
15.124	Miltenyi Biomedicine GmbH	381
15.124.1	CliniMACS Prodigy® system	381
15.124.2	Miltenyi Biotec's CAR-T Product Pipeline.....	382
15.125	Minerva Biotechnologies	382
15.126	Mustang Bio.....	383
15.126.1	Key Clinical Programs	383
15.126.2	Proprietary Manufacturing Facility	384
15.127	Nexcella, Inc.	384
15.127.1	NXC-201	384
15.128	Noile-Immune Biotech Inc.	385
15.128.1	PRIME Technology.....	385
15.128.2	Key Pipeline Candidates.....	385
15.129	Novartis International AG	386
15.129.1	T-Charge™ Platform.....	386
15.129.2	Kymriah® (tisagenlecleucel).....	386
15.130	Novatim Immune Therapeutics	387
15.130.1	The IRAE Bifunctional antibody Platform	387
15.130.2	Nanoantibody Screening Platform	387
15.130.3	K2 CAR-T Platform	387

15.130.4	Novatim's R&D Pipeline.....	388
15.131	OneChain Immunotherapeutics.....	388
15.132	OncoC4, Inc.....	389
15.132.1	Role in CAR-T Cell Therapy	389
15.133	Optium Biotechnologies	390
15.133.1	Eumbody System™	390
15.134	OriCell Therapeutics.....	392
15.134.1	Key Products & Pipeline	392
15.135	Orna Therapeutics.....	393
15.135.1	The Circular RNA (oRNA) Platform	393
15.135.2	Primary Target Areas.....	393
15.136	Outpace Bio.....	394
15.136.1	OUTSMART™ Technology	394
15.136.2	OUTLAST™ Technology.....	394
15.136.3	OUTSPACERS™ Technology.....	394
15.136.4	OUTSAFE™ Technology.....	395
15.136.5	OUTDRIVE™ Technology.....	395
15.136.6	R&D Programs.....	395
15.137	PeproMene Bio.....	396
15.137.1	Core Technologies.....	396
15.137.1.1	BAFFR-CAR T cells (PMB-CT01)	396
15.137.1.2	BAFFR CAR-NK Cells.....	396
15.137.1.3	BAFFR Bispecific T Cell Engager (BiTE)	397
15.137.1.4	High-Polyfunctionality CAR Platform.....	397
15.137.2	Key CAR-T-Based Clinical Trials.....	397
15.138	Poseida Therapeutics.....	398
15.138.1	Technologies	398
15.138.2	piggyBac™ DNA Modification System	398
15.138.3	Cas-CLOVER™ Site-Specific Gene Editing.....	398
15.138.4	Allogeneic (T _{SCM})-Rich Platform	399
15.138.5	Booster Molecule Technology	399
15.138.5.1	Solid Tumor & Dual CAR Capabilities.....	399
15.138.6	Key Pipeline Programs	399
15.139	Precigen	400
15.139.1	Core CAR-T Technologies.....	400
15.139.2	Key Clinical Programs	400
15.140	Precision Biosciences	401
15.140.1	Key Features of Precision's CAR-T Platform	401
15.141	Prescient Therapeutics Ltd.....	402
15.141.1	OmniCAR Platform	402
15.141.2	CellPryme-M	402
15.141.3	CellPryme-A.....	403
15.141.4	PTX-100	403
15.142	Priothera, Ltd.....	403
15.142.1	Role in CAR-T and Cellular Therapy	403
15.143	ProMab Biotechnologies, Inc.....	404
15.143.1	Core CAR-T Custom Services.....	404
15.144	PromiCell.....	405
15.144.1	IL-18 Cytokine Armoring (SAVVY-IL18 Platform).....	405
15.145	Regeneron.....	406
15.146	Roche Group	406
15.146.1	Acquisitions & Strategic Direction.....	407
15.146.2	Key CAR-T Programs	407
15.146.3	Target Indications	407
15.147	Sana Biotechnology	408
15.147.1	Key CAR-T-Based Technologies.....	408

15.147.2	Hypoimmune (HIP) Platform (Allogeneic).....	408
15.147.3	Fusogen Platform	408
15.147.4	Ex Vivo Cell Engineering	409
15.148	Senti Bio	409
15.148.1	Core Technology: Gene Circuits & Logic Gates.....	409
15.148.2	Pipeline & Clinical Focus	410
15.148.3	Clinical Status & Regulatory Designations	410
15.149	Shenzhen MagicRNA Biotechnology Co., Ltd.....	411
15.149.1	Technology Platform.....	411
15.149.2	Product Pipeline & Therapeutics	411
15.150	Shenzhen Pregene Biopharma Co., Ltd.	412
15.150.1	Key CAR-T Program.....	412
15.150.2	PRG-1801 (anti-BCMA CAR-T).....	412
15.151	Simnova Biotherapeutics.....	413
15.151.1	BiTE-Armed CAR-T Cells	413
15.152	Strand Therapeutics	414
15.152.1	In Vivo Cell Programming	414
15.152.2	The SignalLock and SignalPath Systems.....	414
15.152.3	Repeat Dosing and Safety.....	415
15.152.4	Therapeutic Indications.....	415
15.153	Synlico, Inc.	415
15.154	TC Biopharm	416
15.154.1	Gamma Delta T (GDT) Cell Platform.....	416
15.154.2	Co-Stim CAR-T Platform	416
15.154.3	CryoTC Technology	416
15.154.4	ImmuniCAR® Platform	417
15.154.5	TC Biopharm's Clinical Programs.....	417
15.155	T-CURX GmbH.....	417
15.155.1	Sleeping Beauty.....	418
15.155.2	Key CAR-T Product Candidate Pipeline	418
15.156	Terumo BCT	419
15.156.1	Quantum Flex	419
15.157	TG Therapeutics.....	419
15.157.1	CAR-T Pipeline & Focus.....	420
15.158	Thermo Fisher Scientific.....	420
15.158.1	Core Tools and Instrumentation for CAR-T Workflows	420
15.158.2	Media, Reagents, and Analytics	421
15.158.3	End-to-End CDMO and CRO Services.....	421
15.159	Tikva Allocell Pte Ltd	422
15.159.1	Core Technology & Pipeline	422
15.160	TriArm Therapeutics	422
15.160.1	FIT™ (Fast-In-Time)	423
15.160.2	FlexTune™	423
15.160.3	OppoTAGs (Adaptors) Technology	423
15.160.4	CD30+ FineTune™ Technology	423
15.160.5	CD3ε FlowTune™ Technology.....	424
15.160.6	Key Clinical Programs	424
15.161	T-Maximum Pharmaceutical.....	425
15.161.1	Core Focus & Pipeline	425
15.162	Ucello Therapeutics.....	426
15.162.1	CBT-X20™ Technology Platform	426
15.162.2	Key Product Candidates	426
15.163	Umoja Biopharma.....	427
15.163.1	VivoVec™ In Vivo Delivery Platform	427
15.163.2	RACR™/CAR In Vivo Cell Expansion/Control Platform	427
15.163.3	TumorTag™ Targeting Platform.....	428

15.163.4	Umoja's R&D Programs.....	428
15.164	Vector BioMed, Inc.	428
15.164.1	The LENTIVERSE Platform.....	429
15.164.2	Context and Global Impact in CAR-T	429
15.164.2.1	Regional Deployment in India	429
15.165	Verismo Therapeutics	430
15.165.1	KIR-CAR Platform	430
15.165.2	R&D Programs.....	430
15.166	Vittoria Biotherapeutics	431
15.166.1	Senza5™ Technology	431
15.167	Waypoint Bio	432
15.167.1	Core Technology & Approach	432
15.167.2	Key Therapeutic Programs	432
15.168	Wugen, Inc.	433
15.168.1	Wugen's CAR-T Program	433
15.169	Xcell Biosciences.....	433
15.169.1	AVATAR™ Platform	434
15.169.2	AVATAR Odyssey™ (Research System).....	434
15.169.3	AVATAR Ai™ (Software).....	434
15.170	Xenetic Biosciences, Inc.	434
15.170.1	Key CAR-T Initiatives.....	435
15.170.2	Clinical & Strategic Milestones	435
15.171	Xyphos Biosciences	435
15.171.1	convertibleCAR-T™	436
15.172	YolTech Therapeutics	436
15.172.1	Core Focus	436

INDEX OF FIGURES

FIGURE 2.1: The Schematic Diagram of CAR Structure	30
FIGURE 5.1: Number of CAR-T Cell Therapy Patent Filings, 2010 to 2025	57
FIGURE 5.2: Patent Filings for Autologous & Allogeneic CAR-Ts Compared, 2015-2025	58
FIGURE 5.3: Patent Filings by CAR-T Generation Type	59
FIGURE 5.4: Patent Filings for Blood Cancers & Solid Tumors Compared, 2015-2025	60
FIGURE 5.5: CAR-T Patent Filings for Autoimmune Diseases	61
FIGURE 5.6: Patent Filings for In Vivo CAR-T Cell Therapies	62
FIGURE 5.7: Distribution of Filed CAR-T Patents by Jurisdiction	63
FIGURE 5.8: Macro Global Patent Portfolio Distribution	69
FIGURE 6.1: The Bedrock Ascent of CAR-T Research Publications, 2010-2025.....	73
FIGURE 6.2: The Allogeneic Ascent over Autologous CAR-T PubMed.gov Publications	74
FIGURE 6.3: The Solid Tumor Breakthrough in CAR-T Research Publications	75
FIGURE 6.4: PubMed Papers on CAR-T In Situ Revolution	76
FIGURE 6.5: PubMed Papers CAR-T's New Frontier of Autoimmune Diseases	77
FIGURE 7.1: Percent Share of CAR-T Clinical Trials by CAR Generation Type	80
FIGURE 7.2: Percent Share of CAR-T Clinical Trials by Co-stimulatory Domains	81
FIGURE 7.3: Percent Share of CAR-T Clinical Trials by Target Disease	82
FIGURE 7.4: Global Share of CAR-T Clinical Trials by Sponsor Type	83
FIGURE 7.5: Percent Share of Top 5 Hospitals & Clinical Centers in CAR-T Clinical Trials	84
FIGURE 7.6: Percent Share of Top 7 Companies in CAR-T Clinical Trials	85
FIGURE 7.7: Percent Share of CAR-T Clinical Trials by Top 7 Academic Institutions	86
FIGURE 7.8: Percent Share of CAR-T Clinical Trials' Study Phases.....	87
FIGURE 7.9: Funders of CAR-T Clinical Trials.....	88
FIGURE 13.1: Sales Revenue Generated by FDA-Approved CAR-T Therapies, 2018-2025.....	214
FIGURE 13.2: Sales Revenue by CAR-T Cell Therapies Approved in China, 2022-2025.....	215

FIGURE 13.3: Sales Revenue Generated by CAR-T Therapies in India, 2023-2025	218
FIGURE 13.4: Estimated Global Market for CAR-T Cell Therapies by Geography, 2025-2035	221
FIGURE 13.5: Estimated Global Market for CAR-T Cell Therapies by Target Antigen, 2025-2035	224
FIGURE 13.6: Percent Share of CAR-T Market by Approved Indication, 2025	226
FIGURE 13.7: Percent Share of CAR-T Market by Sub-Types of Lymphoma, 2025	228
FIGURE 13.8: Percent Share of CAR-T-based Multiple Myeloma Market by Sub-Types	228
FIGURE 13.9: CAR-T Market for Leukemia Indication by Sub-Type	229
FIGURE 14.1: The Percent Shares of Autologous & Allogeneic CAR-T Companies	237
FIGURE 14.2: Percent Share of CAR-T Companies by Generation Type	238

INDEX OF TABLES

TABLE 2.1: Differentiating Features of the Five Generations of CAR-T Cells	31
TABLE 2.2: Research Institutions involved in Early Experiments using 1st Generation CAR-	32
TABLE 2.3: Companies utilizing 2nd Generation CAR-T in their Product Portfolio	33
TABLE 2.4: Companies Utilizing 3rd Generation CAR-T	34
TABLE 2.5: Companies utilizing 4th Generation CAR-T	34
TABLE 2.6: Companies Utilizing 5th Generation CAR-T	35
TABLE 2.7: Companies Developing In Vivo CAR-T Cell Therapies	36
TABLE 2.8: Top Companies in Allogeneic CAR-T Space	37
TABLE 2.9: Companies Developing Armored CAR-T Products	37
TABLE 2.10: Companies Developing Logic-Gated CAR-T Cells	38
TABLE 3.1: Timeline of CAR-T Cell Therapy Development, 1989-2026	39
TABLE 3.1: (CONTINUED)	40
TABLE 4.1: Prominent All-in-One Integrated Instruments for CAR-T Manufacture	48
TABLE 4.2: Prominent Modular & Specialized Expansion Bioreactors	49
TABLE 4.3: Cost Breakdown Matrix (Per-Dose CAR-T Manufacturing COGS)	51
TABLE 4.4: Cost Breakdown Matrix (Per-Dose Allogeneic COGS)	52
TABLE 5.1: Cost of Filing and Securing a CAR-T Therapy Patent	54
TABLE 5.2: Licensing Cost of CAR-T Cell Therapy Patents	55
TABLE 5.3: Top 10 CAR-T Cell Therapy Licensing Deals	56
TABLE 5.4: Top 20 CAR-T Cell Therapy Patent Jurisdictions	64
TABLE 5.5: Top 20 CAR-T Cell Therapy Patent Applicants	65
TABLE 5.6: Top 20 CAR-T Cell Therapy Patent Inventors	66
TABLE 5.7: Top 20 CAR-T Cell Therapy Patent Owners	67
TABLE 5.8: Legal Status of CAR-T Cell Therapy Filed Patents	68
TABLE 5.9: Top 20 Granted CAR-T Cell Therapy Patents	70
TABLE 5.9: (CONTINUED)	71
TABLE 7.1: Cost Breakdown by Clinical Trial Phase	79
TABLE 8.1: Venture Capital Funding in CAR-T Sector, 2024-2026	89
TABLE 8.2: CAR-T Collaboration Deals, 2023- July, 2026	95
TABLE 8.3: Merger & Acquisition Deals in CAR-T Therapy Sector, 2024-2026	102
TABLE 9.1: Globally Approved CAR-T Cell Therapies	110
TABLE 9.2: Dates of Kymriah's Approvals by Regions/Countries	112
TABLE 9.3: Development Pipeline of Kymriah (tisagenlecleucel)	113
TABLE 9.4: Cost Breakdown at Kymriah Certified Centers in the U.S.	115
TABLE 9.5: Kymriah's Competitors	116
TABLE 9.6: Yescarta's Approval by Region/Country	118
TABLE 9.7: Development Timeline of Yescarta	119
TABLE 9.8: Other Therapies Competing with Yescarta	122
TABLE 9.9: Tecartus' Approval Dates by Region/Country	124
TABLE 9.10: Approval History of Tecartus (brexucabtagene autoleucel)	124
TABLE 9.11: Competing Therapies with Tecartus	125
TABLE 9.12: Dates of Approval of Breyanzi by Region/Country	128

TABLE 9.13: Development Timeline of Breyanzi.....	129
TABLE 9.14: Breyanzi's Competitors.....	131
TABLE 9.15: Dates of Approval of Abecma by Region/Country.....	133
TABLE 9.16: Approval History of Abecma.....	134
TABLE 9.17: Abecma's Competitors.....	136
TABLE 9.18: Dates of Approval of Carvykti by Region/Country.....	138
TABLE 9.19: Development Timeline of Carvykti.....	138
TABLE 9.20: Carvykti's Competitors.....	140
TABLE 9.21: Development Timeline of Aucatzyl.....	142
TABLE 9.22: Competing Therapies for Aucatzyl.....	144
TABLE 9.23: Development Timeline of Carteyva.....	146
TABLE 9.24: Competing Therapies for Carteyva.....	148
TABLE 9.25: Yikaida's Development Timeline.....	151
TABLE 9.26: Competing Therapies with Yikaida.....	153
TABLE 9.27: Development Timeline for Zevor-cel.....	155
TABLE 9.28: Approved Competing Therapies against Zevor-cel.....	156
TABLE 9.29: Development Timeline of Yorwida.....	159
TABLE 9.30: Other Approved Competing Therapies against Yorwida.....	160
TABLE 9.31: Development Timeline of Fucaso.....	163
TABLE 9.32: Approved CAR-T & Non CAR-T Therapies with Fucaso.....	165
TABLE 9.33: Development Timeline of Satri-cel.....	167
TABLE 9.34: Approved Non-CAR-T Competing Therapies for Satri-cel.....	169
TABLE 9.35: Development Timeline of Qartemi.....	171
TABLE 9.36: Approved CAR-T & Non-CAR-T Competing Therapies.....	172
TABLE 9.37: Development Timeline of NexCAR19.....	174
TABLE 11.1: Global Cost Breakdown for CAR-T Therapy by Medical Tourism Destination.....	189
TABLE 11.2: Manufacturing Cost of CAR-T Cell Therapy.....	192
TABLE 11.3: Cost of Developing CAR-T Therapy from Discovery to Marketing Approval.....	193
TABLE 11.4: Cost of Developing CAR-T Therapy from Academics to Spinouts.....	193
TABLE 11.5: Global CAR-T Treatment Cost Comparison.....	194
TABLE 11.6: Total Treatment Cost for CAR-T Cell Therapies in the U.S.	194
TABLE 11.7: Total CAR-T Treatment Cost in Europe.....	195
TABLE 11.8: Total CAR-T Treatment Cost in Japan.....	195
TABLE 11.9: Total CAR-T Treatment Cost in South Korea.....	196
TABLE 11.10: Total CAR-T Treatment Cost in Australia.....	196
TABLE 11.11: Total CAR-T Treatment Cost in China.....	197
TABLE 11.12: Total CAR-T Treatment Cost in India.....	197
TABLE 12.1: Key Therapeutic Targets and Mechanisms of CAR-T in the Emerging Scenario.....	198
TABLE 12.2: Overview of Treatment Options for Lymphoblastic Leukemia.....	199
TABLE 12.3: Overview of Treatment Options for B-Cell Lymphomas.....	200
TABLE 12.4: Overview of Treatment Options for Multiple Myeloma.....	201
TABLE 13.1: Sales Revenue Generated by FDA-Approved CAR-T Cell Therapies, 2018-2025.....	213
TABLE 13.2: Sales Revenue by CAR-T Cell Therapies Approved in China, 2022-2025.....	215
TABLE 13.3: Sales Revenue Generated by CAR-T Cell Therapies Approved in India.....	217
TABLE 13.4: Estimated Global Market for CAR-T Cell Therapies by Geography, 2025-2035.....	221
TABLE 13.5: Revenue Generated by CD19 & BCMA Targeting CAR-T Cell Therapies as of 2025.....	222
TABLE 13.6: Estimated Global Market for CAR-T Cell Therapies by Target Antigen, 2025-2035.....	223
TABLE 13.7: Indications Addressed by CAR-T Cell Therapy.....	225
TABLE 14.1: Leading Companies with Second-Generation CAR-Ts.....	231
TABLE 14.2: Leading Companies with Next Generation CAR-Ts.....	232
TABLE 14.3: Comparison of Second Generation & Next-Generation CAR-Ts.....	232
TABLE 14.4: Companies developing Autologous & Allogeneic CAR-T Therapies.....	233
TABLE 14.5: CAR-T Companies by Gene Editing/Modification Technology.....	234
TABLE 14.6: CAR-T Companies by Targeting and Logic Gate Technology.....	235
TABLE 14.7: CAR-T Companies by Indication Specialization.....	236
TABLE 14.8: CAR-T Companies by Production model.....	236

TABLE 15.1: 4immune Therapeutics' R&D Programs	240
TABLE 15.2: A2 Biotherapeutics' RD Pipeline.....	241
TABLE 15.3: AbClon's CAR-T Product Candidates	244
TABLE 15.4: AbelZeta's R&D Pipeline	246
TABLE 15.5: Aleta's Product Candidates	249
TABLE 15.6: Allogene's AlloCAR-T Product Pipeline.....	251
TABLE 15.7: Atara Bio's Next-generation allogeneic CAR-T programs	263
TABLE 15.8: Autolus Therapeutics' R&D Pipeline	264
TABLE 15.9: AvenCell's R&D Pipeline	266
TABLE 15.10: Cabaletta Bio's R&D Pipeline	278
TABLE 15.11: Carina Biotech's Product Pipeline	282
TABLE 15.12: CARsgen's R&D Pipeline	286
TABLE 15.13: Cartesian's R&D Programs	288
TABLE 15.14: Collectis' CAR-T cell Pipeline	290
TABLE 15.15: Chimeric Therapeutics' Product Pipeline	302
TABLE 15.16: Curocell's R&D Programs.....	311
TABLE 15.17: Essen BioTech's CAR-T-Based R&D Pipeline.....	326
TABLE 15.18: EXUMA Biotech's R&D Pipeline.....	330
TABLE 15.19: Fate Therapeutics' CAR-T-Based R&D Programs	332
TABLE 15.20: Galapago's R&D Pipeline for CAR-T.....	335
TABLE 15.21: Guangzhou Bio-gene's R&D Pipeline	344
TABLE 15.22: IASO's Ongoing Clinical Programs using CAR-T.....	346
TABLE 15.23: iCell Gene Therapeutics' R&D Pipeline.....	348
TABLE 15.24: Immuneel's Products in Development.....	349
TABLE 15.25: Immunofoco's R&D Pipeline.....	352
TABLE 15.26: Innovative Cellular Therapeutics' R&D Programs	356
TABLE 15.27: Kelonia Therapeutics' R&D Programs.....	363
TABLE 15.28: Kiragen Bio's R&D Programs	366
TABLE 15.29: Kyverna Therapeutics' R&D Programs	370
TABLE 15.30: Luminary's R&D Programs	376
TABLE 15.31: Lyell Immunopharma's R&D Programs	378
TABLE 15.32: Miltenyi Biotec's CAR-T Product Pipeline	382
TABLE 15.33: Minerva Biotechnologies' Autologous CAR-T Product Pipeline	383
TABLE 15.34: Novatim's R&D Pipeline	388
TABLE 15.35: Optium Biotechnologies' Product Pipeline	391
TABLE 15.36: Outpace Bio's R&D Programs	395
TABLE 15.37: PromiCell's R&D Programs	405
TABLE 15.38: Sana Biotechnologies' R&D Pipeline	409
TABLE 15.39: Simnova Biotherapeutics' CAR-T R7D Pipeline.....	413
TABLE 15.40: TriArm's Clinical Programs	424
TABLE 15.41: Umoja Biopharma's R&D Programs	428
TABLE 15.42: Vittoria Therapeutics' R&D Pipeline	431

About BioInformant

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, BioInformant has collected 18+ years of historical data on the stem cell industry, providing a robust and unusual foundation on which to base its market research.

To date, BioInformant research has been cited by the *Wall Street Journal* and *Vogue Magazine*, as well as quoted by Tony Robbins in his best-selling book, *LifeForce*.

BioInformant operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

